13.3
Impact Factor

Full Text | PDF

Theranostics 2017; 7(7):2067-2077. doi:10.7150/thno.19427 This issue Cite

Review

Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells

Kiwon Ban¹, Seongho Bae², Young-sup Yoon^{2, 3✉}

1. Department of Biomedical Sciences, City University of Hong Kong, Hong Kong;
2. Department of Medicine, Division of Cardiology, Emory University, Atlanta, Georgia, USA;
3. Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.

✉ Corresponding author: Young-sup Yoon, M.D., Ph.D., Department of Medicine, Division of Cardiology, Emory University, 101 Woodruff Dr. WMB 3009, Atlanta, GA, 30322, USA; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea, E-mail: yyoon5edu. More

Abstract

Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) are considered a most promising option for cell-based cardiac repair. Hence, various protocols have been developed for differentiating hPSCs into CMs. Despite remarkable improvement in the generation of hPSC-CMs, without purification, these protocols can only generate mixed cell populations including undifferentiated hPSCs or non-CMs, which may elicit adverse outcomes. Therefore, one of the major challenges for clinical use of hPSC-CMs is the development of efficient isolation techniques that allow enrichment of hPSC-CMs. In this review, we will discuss diverse strategies that have been developed to enrich hPSC-CMs. We will describe major characteristics of individual hPSC-CM purification methods including their scientific principles, advantages, limitations, and needed improvements. Development of a comprehensive system which can enrich hPSC-CMs will be ultimately useful for cell therapy for diseased hearts, human cardiac disease modeling, cardiac toxicity screening, and cardiac tissue engineering.

Keywords: Cardiomyocytes, hPSCs

Citation styles

©2026 Ivyspring International Publisher. Terms of use